Less than a year after drug major Merck & Co dropped development of its AIDS vaccine candidate, V520 (Marketletter November 19, 2007), the USA's government's research facility, the National Institutes of Health, has abandoned the testing of a similar product.
After soliciting and considering broad input from the scientific and HIV advocacy communities, the National Institute of Allergy and Infectious Diseases, part of the NIH, has determined that it will not conduct the HIV vaccine study known as PAVE 100.
However, the NIAID believes the vaccine developed by its Vaccine Research Center is scientifically intriguing and sufficiently different from previously-tested HIV vaccines to consider testing it in a smaller, more focused clinical study. Therefore, the NIAID says it will entertain a proposal for an alternative study with one specific goal: to determine if the vaccine regimen significantly lowers viral load - the amount of HIV in the blood of vaccinated individuals who may later become infected with the virus.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze